Loading company…
Navigator Medicines develops biologic treatments for autoimmune and inflammatory diseases.
Founded in 2024 in New Jersey, Navigator Medicines develops therapies for immune regulation and autoimmune diseases. Its pipeline includes NAV-240, a clinical-stage bispecific antibody targeting OX40L and TNFa. In August 2024, RA Capital Management and Forbion co-led USD 100 million in Series A funding to advance NAV-240 and other antibody programs.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in